ArticleJournal of clinical microbiology2018
Xpert Ultra Can Unambiguously Identify Specific Rifampin Resistance-Conferring Mutations.
Article in Journal of clinical microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis.The Cochrane database of systematic reviews · 2021Pooled it
- Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults.The Cochrane database of systematic reviews · 2019Pooled it
- Genome-wide analyses of Mycobacterium tuberculosis complex isolates reveal insights into circulating lineages and drug resistance mutations in The Gambia.Scientific reports · 2026Article
- Paucibacillary Tuberculosis Drives the Low Positive Predictive Value of Xpert MTB/RIF Ultra for Rifampicin Resistance Detection in Low-Prevalence Settings.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Probe amplifications in the Xpert MTB/RIF Ultra assay for non-tuberculous mycobacteria identified from diabetes mellitus and chronic kidney disease patients in Ethiopia.Scientific reports · 2025Article
- Limitations of the MTB/RIF Assay: An Xpert Review of 4 Clinical Cases.Open forum infectious diseases · 2025Article
- Culture-Free Whole Genome Sequencing ofOpen forum infectious diseases · 2024Article
- GeneXpert MTB/RIF Ultra performance to detect uncommon rpoB mutations in Mycobacterium tuberculosis.BMC research notes · 2023Article
- Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: A case report from Uganda.Journal of clinical tuberculosis and other mycobacterial diseases · 2021Article
- Discordance of the Repeat GeneXpert MTB/RIF Test for Rifampicin Resistance Detection Among Patients Initiating MDR-TB Treatment in Uganda.Open forum infectious diseases · 2021Article
- Identification and Characterization of Mycobacterial Species Using Whole-Genome Sequences.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Comparison of metagenomic next-generation sequencing technology, culture and GeneXpert MTB/RIF assay in the diagnosis of tuberculosis.Journal of thoracic disease · 2020Article
- False Rifampicin Resistance in Xpert Ultra Applied to Lymph Node Aspirate: A Case Report.Open forum infectious diseases · 2020Article
- Automatic Identification of IndividualJournal of clinical microbiology · 2019Article
- Genotyping of Mycobacterium tuberculosis Rifampin Resistance-Associated Mutations by Use of Data from Xpert MTB/RIF Ultra Enables Large-Scale Tuberculosis Molecular Epidemiology Studies.Journal of clinical microbiology · 2019Article
- How Well Do Routine Molecular Diagnostics Detect Rifampin Heteroresistance in Mycobacterium tuberculosis?Journal of clinical microbiology · 2019Article
- Whole genome sequencing of Mycobacterium tuberculosis: current standards and open issues.Nature reviews. Microbiology · 2019Review
- Variable ability of rapid tests to detect Mycobacterium tuberculosis rpoB mutations conferring phenotypically occult rifampicin resistance.Scientific reports · 2019Article
- Added Value of Xpert MTB/RIF Ultra for Diagnosis of Pulmonary Tuberculosis in a Low-Prevalence Setting.Journal of clinical microbiology · 2019Article
- Bridging the TB data gap:PeerJ · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.